{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:04:28Z","timestamp":1786115068447,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jaip.2026.03.029","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:55:57Z","timestamp":1775231757000},"page":"1612-1619.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Attitudes and Practices Regarding Dosing Interval Extension of Biologics in Severe Asthma: A Nationwide Survey and Real-World Data From the Dutch RAPSODI Registry"],"prefix":"10.1016","volume":"14","author":[{"given":"Camiel J.M.","family":"Marijnissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob K.","family":"Sont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur L.","family":"Meulmeester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel W.J.M.","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert-Jan","family":"Braunstahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnoud F.","family":"Aldenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes A.","family":"Kroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Elske","family":"van den Akker-van Marle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewout W.","family":"Steyerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leti","family":"van Bodegom-Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"van Bezouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Hilvering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els J.M.","family":"Weersink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"van der Sar-van der Brugge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin B.","family":"Fieten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Beukert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen M.A.M.","family":"Retera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen T.M.","family":"Oud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renske","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornelis W.","family":"Patberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Macken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle L.","family":"de Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart H.","family":"Conemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"van Velzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilonka H.","family":"van Veen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"van Huisstede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth A.P.M.","family":"Romme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke","family":"Amelink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte A.","family":"van Ruitenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"ten Brinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper H.","family":"Kappen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2026.03.029_bib1","doi-asserted-by":"crossref","first-page":"00238","DOI":"10.1183\/23120541.00238-2022","article-title":"Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register","volume":"8","author":"Soendergaard","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2026.03.029_bib2","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-term therapy response to anti-IL-5 biologics in severe asthma\u2014a real-life evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.03.029_bib3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2147\/JAA.S319572","article-title":"Real-world multicenter experience with mepolizumab and benralizumab in the treatment of uncontrolled severe eosinophilic asthma over 12 months","volume":"14","author":"Kayser","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2026.03.029_bib4","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.jaip.2023.05.047","article-title":"Response to biologics and clinical remission in the adult German Asthma Net Severe Asthma Registry cohort","volume":"11","author":"Milger","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.03.029_bib5","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jaip.2024.05.052","article-title":"Real-world data on tezepelumab in patients with severe asthma in Germany","volume":"12","author":"Biener","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.03.029_bib6","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1080\/02770903.2024.2441887","article-title":"Is it possible to achieve remission in severe asthma? Retrospective analysis of a four-year response in a real-life cohort treated with mepolizumab","volume":"62","author":"Correa-Borit","year":"2025","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2026.03.029_bib7","article-title":"On-treatment clinical remission of severe asthma with real-world longer-term biologic use","volume":"4","author":"Chipps","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaip.2026.03.029_bib8","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.3390\/jcm12082900","article-title":"A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma","volume":"12","author":"Oishi","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaip.2026.03.029_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2500\/aap.2025.46.240084","article-title":"Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: a post-hoc analysis of RELIght study","volume":"46","author":"Papaioannou","year":"2025","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2026.03.029_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1150162","article-title":"Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study","volume":"14","author":"Pavord","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2026.03.029_bib11","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/14737167.2023.2221435","article-title":"Economic evaluation of biological treatments in patients with severe asthma: a systematic review","volume":"23","author":"Alves","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jaip.2026.03.029_bib12","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40273-018-0658-x","article-title":"Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations","volume":"36","author":"McQueen","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jaip.2026.03.029_bib13","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jaci.2013.11.026","article-title":"Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis","volume":"133","author":"Haldar","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.03.029_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2016.08.054","article-title":"A randomized multicenter study evaluating Xolair persistence of response after long-term therapy","volume":"140","author":"Ledford","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.03.029_bib15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/rheumatology\/key244","article-title":"Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors","volume":"58","author":"Brahe","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaip.2026.03.029_bib16","article-title":"Dose reduction of biologics in patients with plaque psoriasis: a review","volume":"15","author":"van Riel","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2026.03.029_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2026.03.029_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2026.03.029_bib20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bcp.13453","article-title":"A step-down protocol for omalizumab treatment in oral corticosteroid-dependent allergic asthma patients","volume":"84","author":"Domingo","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2026.03.029_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s15007-019-1783-3","article-title":"Comparison of extended intervals and dose reduction of omalizumab for asthma control","volume":"28","author":"B\u00f6lke","year":"2019","journal-title":"Allergo J"},{"key":"10.1016\/j.jaip.2026.03.029_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100703","article-title":"Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma","volume":"15","author":"Bolke","year":"2022","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2026.03.029_bib23","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00404-2024","article-title":"Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study)","volume":"64","author":"Soendergaard","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2026.03.029_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01168-2024","article-title":"Stepping down biologics in asthma: is it time to challenge the status quo?","volume":"64","author":"Khurana","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2026.03.029_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107416","article-title":"The perceived waning of biologics in severe asthma","volume":"219","author":"Kroes","year":"2023","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2026.03.029_bib27","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00403-021-02273-4","article-title":"Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide","volume":"314","author":"van Muijen","year":"2022","journal-title":"Arch Dermatol Res"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826002631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826002631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:07:08Z","timestamp":1785974828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219826002631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2213219826002631"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2026.03.029","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Attitudes and Practices Regarding Dosing Interval Extension of Biologics in Severe Asthma: A Nationwide Survey and Real-World Data From the Dutch RAPSODI Registry","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2026.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}